ASMTL

Summary

ASMTL (acetylserotonin O-methyltransferase like, HGNC:751) is a protein-coding gene on chromosome Xp22.3 and Yp11.3, encoding Probable bifunctional dTTP/UTP pyrophosphatase/methyltransferase protein (O95671). Nucleoside triphosphate pyrophosphatase that hydrolyzes dTTP and UTP.

The protein encoded by this gene has an N-terminus that is similar to the multicopy associated filamentation (maf) protein of Bacillus subtilis and to orfE of Escherichia coli, while the C-terminus is similar to N-acetylserotonin O-methyltransferase. This gene is located in the pseudoautosomal region 1 (PAR1) of X and Y chromosomes. Three transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 8623 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 197 total
• MANE Select transcript: NM_004192

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:751
Approved symbol	ASMTL
Name	acetylserotonin O-methyltransferase like
Location	Xp22.3 and Yp11.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000169093
Ensembl biotype	protein_coding
OMIM	300162, 400011
Entrez	8623

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 16 protein_coding, 3 protein_coding_CDS_not_defined

ENST00000381317, ENST00000381333, ENST00000462195, ENST00000463763, ENST00000474865, ENST00000534940, ENST00000861140, ENST00000861141, ENST00000861142, ENST00000861143, ENST00000940599, ENST00000940600, ENST00000940601, ENST00000940602, ENST00000940603, ENST00000940604, ENST00000967039, ENST00000967040, ENST00000967041

RefSeq mRNA: 3 — MANE Select: NM_004192 NM_001173473, NM_001173474, NM_004192

CCDS: CCDS43917, CCDS55362, CCDS55363

Canonical transcript exons

ENST00000381317 — 13 exons

Exon	Start	End
ENSE00001122361	1412732	1412854
ENSE00001122363	1417973	1418116
ENSE00001122372	1418982	1419114
ENSE00001122378	1421658	1421842
ENSE00001122384	1425525	1425687
ENSE00001122391	1427734	1428121
ENSE00001122412	1435694	1435758
ENSE00002288630	1403139	1403489
ENSE00002313299	1452748	1452909
ENSE00003486552	1432269	1432377
ENSE00003500487	1435022	1435083
ENSE00003580452	1442186	1442317
ENSE00003664640	1439097	1439144

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 96.46.

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	96.46	gold quality
parotid gland	UBERON:0001831	95.95	gold quality
renal glomerulus	UBERON:0000074	94.86	gold quality
metanephric glomerulus	UBERON:0004736	94.65	gold quality
endothelial cell	CL:0000115	94.63	gold quality
parietal pleura	UBERON:0002400	93.79	gold quality
seminal vesicle	UBERON:0000998	93.73	gold quality
pons	UBERON:0000988	93.33	gold quality
substantia nigra pars compacta	UBERON:0001965	93.29	gold quality
epithelium of nasopharynx	UBERON:0001951	93.28	gold quality
corpus epididymis	UBERON:0004359	93.28	gold quality
thymus	UBERON:0002370	93.26	gold quality
substantia nigra pars reticulata	UBERON:0001966	93.14	gold quality
germinal epithelium of ovary	UBERON:0001304	92.81	gold quality
stromal cell of endometrium	CL:0002255	92.54	gold quality
synovial joint	UBERON:0002217	92.32	gold quality
saphenous vein	UBERON:0007318	92.29	gold quality
urethra	UBERON:0000057	92.25	gold quality
layer of synovial tissue	UBERON:0007616	92.25	gold quality
pleura	UBERON:0000977	92.19	gold quality
middle temporal gyrus	UBERON:0002771	92.15	gold quality
metanephros	UBERON:0000081	91.90	gold quality
apex of heart	UBERON:0002098	91.86	gold quality
periodontal ligament	UBERON:0008266	91.83	gold quality
caput epididymis	UBERON:0004358	91.82	gold quality
penis	UBERON:0000989	91.78	gold quality
lateral nuclear group of thalamus	UBERON:0002736	91.75	gold quality
kidney epithelium	UBERON:0004819	91.68	gold quality
adenohypophysis	UBERON:0002196	91.67	gold quality
popliteal artery	UBERON:0002250	91.60	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-8498	yes	8.87
E-MTAB-6142	no	128.06
E-MTAB-6524	no	118.96
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

6 targeting ASMTL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-6883-3P	97.97	67.35	643
HSA-MIR-134-5P	97.11	66.52	976
HSA-MIR-3118	97.11	66.58	984
HSA-MIR-5579-5P	96.32	68.54	730

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	asmtl	ENSDARG00000021433
rattus_norvegicus	Asmtl	ENSRNOG00000028166
drosophila_melanogaster	CG9515	FBGN0032077
caenorhabditis_elegans	dod-18	WBGENE00008316

Paralogs (1): ASMT (ENSG00000196433)

Protein

Protein identifiers

Probable bifunctional dTTP/UTP pyrophosphatase/methyltransferase protein — O95671 (reviewed: O95671)

All UniProt accessions (1): O95671

UniProt curated annotations — full annotation on UniProt →

Function. Nucleoside triphosphate pyrophosphatase that hydrolyzes dTTP and UTP. Can also hydrolyze CTP and the modified nucleotides pseudo-UTP, 5-methyl-UTP (m(5)UTP) and 5-methyl-CTP (m(5)CTP). Has weak activity with dCTP, 8-oxo-GTP and N(4)-methyl-dCTP. May have a dual role in cell division arrest and in preventing the incorporation of modified nucleotides into cellular nucleic acids. In addition, the presence of the putative catalytic domain of S-adenosyl-L-methionine binding in the C-terminal region argues for a methyltransferase activity.

Subunit / interactions. Homodimer.

Tissue specificity. Widely expressed. In adult, highly expressed in pancreas, placenta, fibroblast, thymus, prostate, testis, ovary and colon. Expressed at lower levels in spleen, small intestine and leukocytes. In fetus, expressed at high levels in the lung and kidney and at lower level in brain and liver.

Cofactor. Pyrophosphatase activity requires a divalent metal cation.

Miscellaneous. The gene coding for this protein is located in the pseudoautosomal region 1 (PAR1) of X and Y chromosomes. It represents a unique fusion product of 2 different genes of different evolutionary origin and function. The N-terminus is homologous to the bacterial maf/orfE genes and the C-terminus is homologous to ASMT. Exon duplication, exon shuffling and gene fusion seem to be common characteristics of the PAR1 region.

Similarity. In the N-terminal section; belongs to the Maf family. YhdE subfamily. In the C-terminal section; belongs to the class I-like SAM-binding methyltransferase superfamily. Cation-independent O-methyltransferase family.

Isoforms (3)

UniProt ID	Names	Canonical?
O95671-1	1	yes
O95671-2	2
O95671-3	3

RefSeq proteins (5): NP_001166944, NP_001166945, NP_001411122, NP_001411123, NP_004183* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001077	COMT_C	Domain
IPR003697	Maf-like	Family
IPR012967	COMT-like_dimerisation	Domain
IPR016461	COMT-like	Family
IPR029001	ITPase-like_fam	Homologous_superfamily
IPR029063	SAM-dependent_MTases_sf	Homologous_superfamily
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily

Pfam: PF00891, PF02545, PF08100

Catalyzed reactions (Rhea), 6 shown:

• CTP + H2O = CMP + diphosphate + H(+) (RHEA:27762)
• dTTP + H2O = dTMP + diphosphate + H(+) (RHEA:28534)
• UTP + H2O = UMP + diphosphate + H(+) (RHEA:29395)
• 5-methyl-CTP + H2O = 5-methyl-CMP + diphosphate + H(+) (RHEA:58732)
• 5-methyl-UTP + H2O = 5-methyl-UMP + diphosphate + H(+) (RHEA:58736)
• psi-UTP + H2O = psi-UMP + diphosphate + H(+) (RHEA:58740)

UniProt features (53 total): mutagenesis site 11, helix 10, strand 8, modified residue 5, region of interest 3, site 3, sequence conflict 3, binding site 3, splice variant 2, sequence variant 2, chain 1, compositionally biased region 1, active site 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
2P5X	X-RAY DIFFRACTION	2
6XI4	X-RAY DIFFRACTION	2.22
6XI5	X-RAY DIFFRACTION	2.61

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O95671-F1	87.64	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (4): 89 (important for substrate specificity; for pyrophosphatase activity); 179 (important for substrate specificity; for pyrophosphatase activity); 88 (proton acceptor; for pyrophosphatase activity); 23 (important for substrate specificity; for pyrophosphatase activity)

Ligand- & substrate-binding residues (3): 482; 508–510; 525

Post-translational modifications (5): 21, 228, 234, 239, 421

Mutagenesis-validated functional residues (11):

Position	Phenotype
19	loss of pyrophosphatase activity.
21	loss of pyrophosphatase activity.
23	decrease in pyrophosphatase activity.
24	loss of pyrophosphatase activity.
44	loss of pyrophosphatase activity.
57	loss of pyrophosphatase activity.
65	loss of pyrophosphatase activity.
88	loss of pyrophosphatase activity.
99	loss of pyrophosphatase activity.
179	loss of pyrophosphatase activity.
179	strong decrease in pyrophosphatase activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 85 (showing top): FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN, KYNG_DNA_DAMAGE_BY_4NQO, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP, RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN, ONDER_CDH1_TARGETS_2_UP, SCHLOSSER_SERUM_RESPONSE_DN, HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_UP, BASAKI_YBX1_TARGETS_DN, GOBP_METHYLATION, GARY_CD5_TARGETS_UP, BLALOCK_ALZHEIMERS_DISEASE_DN, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, RUTELLA_RESPONSE_TO_HGF_UP

GO Biological Process (2): nucleotide metabolic process (GO:0009117), methylation (GO:0032259)

GO Molecular Function (9): O-methyltransferase activity (GO:0008171), dTTP diphosphatase activity (GO:0036218), UTP diphosphatase activity (GO:0036221), protein dimerization activity (GO:0046983), nucleoside triphosphate diphosphatase activity (GO:0047429), protein binding (GO:0005515), methyltransferase activity (GO:0008168), transferase activity (GO:0016740), hydrolase activity (GO:0016787)

GO Cellular Component (1): cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleoside triphosphate diphosphatase activity	2
catalytic activity	2
nucleoside phosphate metabolic process	1
metabolic process	1
methyltransferase activity	1
protein binding	1
pyrophosphatase activity	1
binding	1
transferase activity, transferring one-carbon groups	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2357 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ASMTL	AKAP17A	Q02040	909
ASMTL	SLC25A6	P12236	885
ASMTL	PLCXD1	Q9NUJ7	743
ASMTL	DHRSX	Q8N5I4	740
ASMTL	GTPBP6	O43824	728
ASMTL	NR1I2	O75469	707
ASMTL	ZBED1	O96006	667
ASMTL	P2RY8	Q86VZ1	667
ASMTL	SHOX	O15266	628
ASMTL	PPP2R3B	Q9Y5P8	603
ASMTL	EIF1AX	P47813	574
ASMTL	CSF2RA	P15509	568
ASMTL	PUDP	Q08623	567
ASMTL	SPRY3	O43610	542
ASMTL	RBM44	Q6ZP01	518

IntAct

80 interactions, top by confidence:

A	B	Type	Score
ASMTL	TDO2	psi-mi:“MI:0915”(physical association)	0.910
TDO2	ASMTL	psi-mi:“MI:0915”(physical association)	0.910
KRT31	ASMTL	psi-mi:“MI:0915”(physical association)	0.720
ASMTL	KRT31	psi-mi:“MI:0915”(physical association)	0.720
ASMTL	KRT40	psi-mi:“MI:0915”(physical association)	0.560
ASMTL	PNMA1	psi-mi:“MI:0915”(physical association)	0.560
KRT40	ASMTL	psi-mi:“MI:0915”(physical association)	0.560
PNMA1	ASMTL	psi-mi:“MI:0915”(physical association)	0.560
KRT34	ASMTL	psi-mi:“MI:0915”(physical association)	0.560
ASMTL	REL	psi-mi:“MI:0915”(physical association)	0.560
ASMTL	GORASP2	psi-mi:“MI:0915”(physical association)	0.560
ASMTL	ZNF655	psi-mi:“MI:0915”(physical association)	0.560
ASMTL	DCTN1	psi-mi:“MI:0915”(physical association)	0.560
	ASMTL	psi-mi:“MI:0915”(physical association)	0.560
OPTN	ASMTL	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (56): ASMTL (Two-hybrid), ASMTL (Two-hybrid), ASMTL (Two-hybrid), PNMA1 (Two-hybrid), KRT40 (Two-hybrid), ASMTL (Two-hybrid), ASMTL (Two-hybrid), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS), ASMTL (Affinity Capture-MS)

ESM2 similar proteins: A0JN95, A4IF87, A6NJ78, B5DEQ3, B7ZMP1, D3ZLY0, E9Q4Z2, F1QDI9, G1SPE9, O14717, O15228, O22268, O55055, O95453, O95671, P37287, P69341, P97770, Q05B63, Q08J23, Q0V8R7, Q0VGM9, Q10D00, Q1HFZ0, Q2T9W2, Q4G073, Q5R5T5, Q5R962, Q5R9W8, Q5RC51, Q5RJZ1, Q6GR37, Q6H1L8, Q6NYU2, Q6YJI5, Q7TNK6, Q7YS61, Q7Z4G4, Q8JZM0, Q8R2Y8

Diamond homologs: A0A084R1I1, A0A0N9HMN6, A0A1L9UR19, A0A1W5SMT6, A0A2G5IC53, A0A2S1WC15, A0A2V5HP22, A0A348AXX3, A0A443HJY8, A0A4P8WAD3, A0A7T8J1Z8, A1DA61, A2QBF0, A5ABG3, A9X7L0, B0ZB56, B0ZB57, B1P123, B4XY98, B6VJS4, B8NJH3, B8NY85, B9WZX2, C7SDN9, C9K7C0, D3H5H5, D3KY98, D3KY99, D3KYA0, D7PI16, D7PI18, E7FL15, E9KMQ4, G3XSI5, I1RF60, I3PLQ7, M2YKT1, O24305, O24529, O95671

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

197 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	7
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2359 predictions. Top by Δscore:

Variant	Effect	Δscore
X:1412850:GTCAC:G	acceptor_gain	1.0000
X:1412851:TCAC:T	acceptor_gain	1.0000
X:1412852:CACC:C	acceptor_gain	1.0000
X:1421653:GCTAC:G	donor_loss	1.0000
X:1421654:CTA:C	donor_loss	1.0000
X:1421655:TACCT:T	donor_loss	1.0000
X:1421656:AC:A	donor_loss	1.0000
X:1421657:C:CT	donor_loss	1.0000
X:1425479:TCC:T	donor_gain	1.0000
X:1425686:CC:C	acceptor_gain	1.0000
X:1425686:CCCTG:C	acceptor_loss	1.0000
X:1425687:CC:C	acceptor_gain	1.0000
X:1425688:C:CC	acceptor_gain	1.0000
X:1427746:AAAGC:A	donor_gain	1.0000
X:1427815:AG:A	donor_gain	1.0000
X:1432263:ACTC:A	donor_loss	1.0000
X:1432264:CTCA:C	donor_loss	1.0000
X:1432265:TCAC:T	donor_loss	1.0000
X:1432266:CA:C	donor_loss	1.0000
X:1432267:A:AC	donor_gain	1.0000
X:1432267:A:C	donor_loss	1.0000
X:1432268:C:CA	donor_gain	1.0000
X:1432268:CA:C	donor_gain	1.0000
X:1432268:CAT:C	donor_gain	1.0000
X:1432268:CATG:C	donor_gain	1.0000
X:1432374:TGGT:T	acceptor_gain	1.0000
X:1432375:GGTCT:G	acceptor_loss	1.0000
X:1432377:TCTG:T	acceptor_loss	1.0000
X:1432378:C:CC	acceptor_gain	1.0000
X:1432378:CT:C	acceptor_loss	1.0000

AlphaMissense

8114 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
Y:1439119:A:T	V84D	0.995
Y:1452771:G:T	R24S	0.994
Y:1452784:G:C	S19R	0.993
Y:1452784:G:T	S19R	0.993
Y:1452786:T:G	S19R	0.993
Y:1442226:G:T	A62D	0.992
Y:1428035:A:G	F199S	0.990
Y:1439116:A:T	I85N	0.990
Y:1442216:C:A	K65N	0.990
Y:1442216:C:G	K65N	0.990
Y:1439111:C:G	A87P	0.989
Y:1428046:G:C	N195K	0.988
Y:1428046:G:T	N195K	0.988
Y:1439107:T:A	D88V	0.988
Y:1442215:C:G	A66P	0.988
Y:1442218:T:G	K65Q	0.988
Y:1442238:G:T	A58D	0.988
Y:1452788:G:T	A18D	0.988
Y:1428038:C:T	G198E	0.987
Y:1439108:C:G	D88H	0.987
Y:1439113:C:T	G86E	0.986
Y:1442227:C:G	A62P	0.986
Y:1452791:A:G	L17P	0.986
Y:1419004:G:C	F452L	0.985
Y:1419004:G:T	F452L	0.985
Y:1419006:A:G	F452L	0.985
Y:1435048:A:T	V125D	0.985
Y:1428115:T:A	K172N	0.983
Y:1428115:T:G	K172N	0.983
Y:1435051:C:T	G124D	0.983

dbSNP variants (sampled 300 via entrez): RS111066028 (X:1407046 A>G), RS111066034 (X:1424402 G>A,C), RS111161743 (X:1406777 C>A,G,T), RS111161744 (X:1406789 C>G), RS111161745 (X:1406818 A>G), RS111161747 (X:1416381 A>C), RS111161748 (X:1416385 G>A), RS111161749 (X:1416680 G>A), RS111162408 (X:1416172 T>C,G), RS111162409 (X:1416176 G>A), RS111162410 (X:1416208 A>G), RS111162411 (X:1416248 G>C), RS111162412 (X:1416252 G>A,C), RS111162413 (X:1416315 C>A), RS111162414 (X:1416319 A>G)

Disease associations

OMIM: gene MIM:300162, MIM:400011 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): myoepithelial tumor (MONDO:0002380), primary amenorrhea (MONDO:1060208)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	5
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Decitabine	affects expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
bisphenol A	increases expression	1
trichostatin A	increases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	increases expression	1
nickel sulfate	increases expression	1
coumarin	increases phosphorylation	1
pentanal	increases expression	1
entinostat	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Vorinostat	affects cotreatment, affects expression	1
Aldehydes	increases expression	1
Benzene	increases expression	1
Caffeine	decreases phosphorylation	1
Carmustine	decreases expression	1
Cisplatin	affects expression	1
Copper	affects binding, increases expression	1
Disulfiram	affects binding, increases expression	1
Estradiol	affects expression	1
Ethyl Methanesulfonate	decreases expression	1
Folic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SD64	HAP1 ASMTL (-) 1	Cancer cell line	Male
CVCL_XL60	HAP1 ASMTL (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

6 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis
NCT07164248	Not specified	COMPLETED	Evaluation of Bone Mineral Density Indications and Outcomes in Female Adolescents: Implications for Early Detection of Osteopenia/Osteoporosis and Gynecologic Practice